Joe Scandura, MD, PhD

Articles

Dr Scandura on the SENTRY-2 Trial of Single-Agent Selinexor in JAK Inhibitor–Naive Myelofibrosis

October 16th 2024

Joseph M. Scandura, MD, PhD, discusses the phase 2 SENTRY-2 study evaluating single-agent selinexor in JAK inhibitor–naive myelofibrosis.

Future Perspectives in the Treatment of Polycythemia Vera

September 22nd 2023

John Mascarenhas, MD, and Joe Scandura, MD, PhD, close their discussion by highlighting what to look forward to in the future of polycythemia vera treatment.

Ruxolitinib in the Treatment of PV

September 15th 2023

Key opinion leaders discuss data on the use of ruxolitinib in patients with polycythemia vera.

Influence of Driver Mutations on Response to Ropeginterferon Alpha-2b in Patients with PV

September 15th 2023

Joe Scandura, MD, PhD, explains how a patient with polycythemia vera and driver mutations responds to interferon treatment.

Treatment Approaches for High-Risk Patients With PV

September 8th 2023

Drs Joe Scandura and John Mascarenhas discuss their treatment approaches for high-risk patients with polycythemia vera.

Key Trials in the Treatment of PV

September 8th 2023

Experts review critical trial data in the treatment of patients with polycythemia vera.

Managing Toxicities of Ropeginterferon Alpha-2b in Patients With PV

September 1st 2023

Joe Scandura, MD, PhD, summarizes the toxicity profile of interferon therapy in patients with polycythemia vera.

Managing Toxicities of Hydroxyurea in Patients With PV

September 1st 2023

Drs John Mascarenhas and Joe Scandura review the toxicities seen with the non-specific chemotherapeutic agent hydroxyurea in patients with polycythemia vera.

Factoring Symptom Burden Into Treatment Decision-Making for Patients With PV

August 25th 2023

Joe Scandura, MD, PhD, explains how he considers individual symptom burden when deciding on a treatment regimen for a patient with polycythemia vera.

Reducing Risk of Thrombosis in Patients With PV

August 25th 2023

Key opinion leaders discuss their treatment targets for low- and high-risk patients with polycythemia vera.

Importance of Bone Marrow Biopsy For Diagnosis of PV

August 18th 2023

Experts explain the critical importance of obtaining bone marrow biopsies for accurately diagnosing polycythemia vera.

Typical Presentation of a Patient With PV

August 18th 2023

John Mascarenhas, MD, and Joe Scandura, MD, PhD, detail the typical presentation of a patient with polycythemia vera in their clinical practices.

Reducing Risk of Disease Progression in Patients With PV

August 11th 2023

Dr Joe Scandura discusses how he considers risk of disease progression when during therapeutic decision making for a patient with polycythemia vera.

Risk Assessment in Patients With Polycythemia Vera (PV)

August 11th 2023

Joe Scandura, MD, PhD, reviews how he approaches risk assessment in patients with polycythemia vera and how risk score helps to determine treatment.